HIMS US · Hims & Hers Health, Inc.MW GOBLIN RESEARCH
HIMS: Margin and cash validation come before revenue recovery
Analysis date
Published
As of 2026-09-30, the stance is wait and see. A recovery in U.S. weight-management demand is positive, but declining profitability and acquisition-payment burdens constrain improvement in per-share value. At the queried share price of $28.78, margin recovery and cash generation after investment are needed to support an undervaluation case.
Read the reasoning behind the analysis
The full report includes key metrics, detailed analysis, valuation, and sources.
Read up to three full reports daily without signing in.
Read the full reportWhat this report covers
- Revenue growth has not translated into profit growth
- The cost of acquisition-driven growth is cash outflow or dilution